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Abstract: Nutrition is one of the most important modifiable factors involved in the 
development and maintenance of good bone health. Calcium and Vitamin D have confirmed 
and established roles in the maintenance of proper bone health. However, other nutritional 
factors could also be implicated. This review will explore the emerging evidence of the 
supporting role of certain B Vitamins as modifiable factors associated with bone health. 
Individuals with high levels of homocysteine (hcy) exhibit reduced bone mineral density (BMD), 
alteration in microarchitecture and increased bone fragility. The pathophysiology caused by high 
serum homocysteine is not completely clear regarding fractures, but it may involve factors, such 
as bone mineral density, bone turnover, bone blood flow and collagen cross-linking. It is 
uncertain whether supplementation with B Vitamins, such as folate, Vitamin B1, and 
Vitamin B6, could decrease hip fracture incidence, but the results of further clinical trials should 
be awaited before a conclusion is drawn. 
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Many factors contribute to bone health. Bone is a dynamic tissue in a constant state of remodeling. 
Bone formation exceeds bone resorption generally in the first three decades of life, the age when peak 
bone mass is achieved. After this time, bone resorption is favored, and bone loss ensues [1].  
Osteoporosis is a chronic, multifactorial disorder characterized by low bone mass and microarchitectural 
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deterioration of bone tissue [2,3]. Deterioration of bone quality predisposes affected individuals to an 
increased risk of fragility fracture [1,4]. The most common osteoporotic fracture sites are the spine, hip 
and wrist, with both spine and hip fractures accompanied by considerable disability and increased 
morbidity and mortality [1,5], in addition to increased social and economic burden [3]. This burden is 
expected to increase substantially in Europe in the coming decades due to a rise in life expectancy [6]. 
Combined supplementation of calcium and Vitamin D have been proven to reduce bone loss and fracture 
incidence [7]. However, it is possible that nutritional factors not typically linked with bone health could 
play a protective role for bone. Association studies have identified vitamins related to fractures or bone 
mineral density [8]. Emerging evidence in groups of healthy individuals suggests a protective association 
of certain B Vitamins, in particular Vitamin B12 and folic acid, a detrimental effect of homocysteine and 
the 677C_T polymorphism in the gene encoding the folate metabolizing methylene tetrahydrofolate 
reductase (MTHFR) enzyme [3,9]. High concentrations of homocysteine and low levels of Vitamin B12 
and folate, the main determinants in the metabolism of homocysteine [10,11], have been associated with low 
bone mineral density (BMD) and a higher risk of fractures in the elderly [3]. Analyses of randomized 
controlled trials have shown that supplementation of folic acid (0.5–5 mg day−1) has resulted in reducing 
the levels of homocysteine in blood up to 25%; the co-supplementation of folic acid and Vitamin B12 
(0.5–5 mg day−1 and 500 mcg day−1, respectively) provided a further reduction of 7% with a decrease in 
serum total homocysteine by 32% [12]. To date, the mechanisms linking homocysteine to increased fracture 
risk have not yet been clarified. It is known that serum homocysteine is regulated by Vitamin B12 and  
folic acid, and supplementation with these vitamins decreases serum homocysteine levels. It is also 
known that folate, Vitamin B12, Vitamin B6 and riboflavin are involved in the metabolism of an  
S-containing amino acid, homocysteine. Homocysteine metabolism links the methionine cycle with the 
folate cycle. A first link between homocysteine (hcy) and the skeleton has been noted in studies of 
hyperhomocysteinuria, a metabolic disorder characterized by exceedingly high levels of hcy in the 
plasma and urine. Individuals with hyperhomocysteinuria exhibit numerous skeletal defects, including 
reduced BMD and osteopenia [13]. Homocysteine comes from the breakdown of methionine, one of the 
essential amino acids used for protein synthesis. Homocysteine can be converted to cystathionine with 
Vitamin B6 and further to cysteine. Alternatively, homocysteine can be remethylated to methionine with 
help from vitamin B12 [8]. The latter reaction is catalyzed by methionine synthase and requires  
5-methyltetrahydrofolate, the principal circulating form of folate, and Vitamin B12 in its co-factor form, 
methylcobalamin. The formation of 5-methyltetrahydrofolate is catalyzed by the MTHFR enzyme [1] 
(Figure 1). 
The pathway for the conversion of homocysteine to methionine is the transfer of a methyl group  
from 5-methyltetrahydrofolate to homocysteine, catalyzed by the Vitamin B12-dependent enzyme,  
methionine synthase [8]. Reducing elevated homocysteine levels through folic acid and Vitamin B12 
supplementation could theoretically ensure proper bone health and prevent osteoporosis. However,  
at present, no consensus has been reached on the magnitude of the association between Vitamin B12, folate, 
homocysteine and bone health, nor on the possible effect of Vitamin B12 and folate supplementation on 
bone health [3]. 
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Figure 1. Homocysteine metabolism: B12 (Vitamin B12), B6 (vitaminb6), MTHFR 
(methylene tetrahydrofolate reductase). 
2. Nutrition and B Vitamins 
The B Vitamins are thiamine (B1), riboflavin (B2), niacin (B3, also called nicotinamide or nicotinic  
acid amide), pantothenic acid (B5), pyridoxine (B6), biotin (B7), folic acid or folate (B9) and  
cobalamin (B12). B Vitamins play an important role in growth, development and other bodily functions 
by promoting enzymatic activity. Food sources of Vitamin B are both plant and animal. Vitamin B 
deficiency can lead to the emergence of many diseases. An understanding of how a deficiency in B 
Vitamins influences the health of the population could lead to targeted prevention for the benefit of  
public health. Governments all over the world have therefore started recommending levels of daily intake 
of Vitamin B in order to keep the population healthy. Therefore, recommended levels, known as 
recommended dietary allowance (RDA) and tolerable upper intake level (UL), have been established. In 
addition to calcium and Vitamin D, which are already well known, B Vitamin (especially Vitamin B6, 
B9 and B12) are also involved in bone health [14]. 
A healthy diet can provide all the B Vitamin necessary to keep the body healthy, easily reaching the 
recommended dietary intakes. However, many people have an unbalanced diet, low in healthy foods 
(fruits, vegetables, meat, fish, cheese, eggs, legumes and cereals), meaning that they do not get the 
recommended amounts. Especially in older persons, those with the highest fracture risk, intake is often 
a problem, and more importantly, the absorption of Vitamin B12 is reduced, leading to Vitamin B12 
deficiencies in the elderly. In fact, some B Vitamin can be obtained from vegetable foods, while others 
(such as Vitamin B12) can be obtained only from animal products [14]. B Vitamin are water-soluble, 
meaning that any excess intake is largely excreted in the urine. Supplements containing B Vitamin are 
generally thought to be safe, but still should not be taken in very large doses. Possible side effects  
can vary, depending on which B vitamin is taken [15]. 
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Table 1 lists the recommended dietary allowance (RDA) for B Vitamin important for bone health. It 
also lists the foods richest in Vitamin B6, Vitamin B12 and folic acid according to the National Nutrient 
Database for Standard Reference of the United States Department of Agriculture (USDA). 
Table 1. RDAs (recommended dietary allowances and adequate intakes) for micronutrients.  
VIT.B RDA UL (≥19 years) Food Serving mcg 
Vitamin 
B6 
Men: 1.3 mg day−1  
(19–50 years),  
1.7 mg day−1  
(>50 years)  
Women: 1.3 mg day−1 
(19–50 years),  




100 mg day−1 
Fortified breakfast cereal 1 cup 0.5–2.5 
Salmon, wild (cooked) 3 ounces * 0.48–0.80 
Potato, Russet, with skin (baked) 1 medium 0.70 
Turkey, light meat (cooked) 3 ounces 0.69 
Avocado 1 medium 0.52 
Chicken, light meat without skin (cooked) 3 ounces 0.51 
Spinach (cooked) 1 cup 0.44 
Banana 1 medium 0.43 
Dried plums, pitted 1 cup 0.36 
Banana 1 medium 0.43 
Hazelnuts (dry roasted) 1 ounce 0.18 
Vegetable juice cocktail 6 ounces 0.13 
folic 
acid 
Men and women:  
400 μg day−1 
Men and 
women:  
1000 μg day−1 
Fortified breakfast cereal 1 cup 200–400 
Orange juice (from concentrate) 6 ounces 83 
Spinach (cooked) 1/2 cup 132 
Asparagus (cooked) 
1/2 cup  
(~6 spears) 
134 
Lentils (cooked) 1/2 cup 179 
Garbanzo beans (cooked) 1/2 cup 141 
Lima beans (cooked) 1/2 cup 78 
Bread 1 slice 20 (folic acid) § 
Pasta (cooked) 1 cup 60 (folic acid) § 
Rice (cooked) 1 cup 60 (folic acid) § 
Vitamin 
B12 
Men and women:  
2.4 μg day−1 
ND 
Clams (steamed) 3 ounces 84.1 
Mussels (steamed) 3 ounces 20.4 
Mackerel (Atlantic, cooked, dry-heat) 3 ounces * 16.1 
Crab (Alaska king, steamed) 3 ounces 9.8 
Beef (lean, plate steak, cooked, grilled) 3 ounces 6.9 
Salmon (chinook, cooked, dry-heat) 3 ounces 2.4 
Rockfish (cooked, dry-heat) 3 ounces 1.0 
Milk (skim) 8 ounces 0.9 
Turkey (cooked, roasted) 3 ounces 0.8 
Brie (cheese) 1 ounce 0.5 
Egg (poached) 1 large 0.4 
Chicken (light meat, cooked, roasted) 0 ounces 0.3 
UL: tolerable upper intake level, established by the Food and Nutrition Board of the U.S. Institute of Medicine, the UL is the highest level 
of daily intake of a specific nutrient likely to pose no risk of adverse health effects in almost all individuals of a specified age; ND: no 
date, list of the nutrient content of specific foods according to the USDA National Nutrient Database for Standard Reference; * A  
three-ounce serving of meat or fish is about the size of a deck of cards; § To increase the revenue of folic acid in the population, the Food 
and Drug Administration (FDA) required the addition of 1.4 milligrams (mg) of folic acid per kilogram (kg) of grain to be added to refined 
grain products, which are already enriched with niacin, thiamin, riboflavin and iron, as of 1 January 1998. 
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2.1. Vitamin B6 
2.1.1. Food Sources 
Humans cannot synthesize Vitamin B6, and therefore, it must be obtained from the diet. Vitamin B6 
is found in a variety of foods, including fish, poultry, nuts, legumes, potatoes and bananas. The analysis 
of data collected in the NHANES 2003–2004 showed that, in the United States, Vitamin B6 intake from 
food is estimated to be an average of 1.9 mg day−1 [16]. However, despite the fact that these values are 
well above those indicated by the RDA, we know that the serum levels of Vitamin B6 were low for all 
age groups. This phenomenon could be explained by the fact that many plant foods contain a unique 
form of Vitamin B6, called pyridoxine glucoside; this form of Vitamin B6 appears to be only about half 
as bioavailable as Vitamin B6 from other food sources or supplements [17]. Vitamin B6 in a mixed diet 
has been found to be approximately 75% bioavailable [13]. 
2.1.2. Supplements 
Those who follow a very strict vegetarian diet might need to increase their Vitamin B6 intake by 
eating foods fortified with Vitamin B6 or by taking a supplement. Doses of Vitamin B6 above 200 mg 
were associated with cancer and neurotoxicity [18]. Currently, the relationship between this Vitamin and 
cases of colorectal cancer are still under discussion [19]; the relationship between excess Vitamin B6 and 
neuropathy is more clear [18,20]. 
2.2. Folic Acid 
2.2.1. Food Sources 
Green leafy vegetables are foods especially rich in folate. Table 1 shows the main sources of folate 
based on the content of folic acid in micrograms (mcg). Citrus fruits, legumes and fortified cereals are 
also good sources of folate [13]. Blood homocysteine levels have decreased since the FDA mandated 
folic acid fortification of grain supply [21]. 
2.2.2. Supplements 
The principal form of supplementary folate is folic acid. It is available in single ingredient  
and combination products, such as B-complex Vitamin and multivitamins. The fortification of flour  
foods [22] has markedly reduced the incidence of birth defects, especially those of the central  
nervous system, such as dysfunction of the neural tube (DTN), anencephaly and spina bifida [23,24], 
and other types of skull malformations and heart defects [25,26]. Woman who decide to conceive are 
strongly recommended to take 400 mcg (0.4 mg) of folic acid per day to prevent the onset of these serious 
birth defects [23]. A folic acid supplementation ≥0.4 mg day−1 seems to be associated with an increased 
risk of cancer [27], but the role of folate is complex and still not clear. It might depend on the dose and 
timing of supplementation during carcinogenesis. It is thought to protect against the initiation of cancer, 
while it may enhance growth and progression. The risk of toxicity from folic acid is low, because folate 
is a water-soluble vitamin and is regularly removed from the body through urine [28], so although the 
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risk of intakes >1000 μg day−1 (the FDA’s safe upper limit of daily intake) would be minimal, the actual 
effect of folate intake has yet to be determined [29]. 
2.3. Vitamin B12 
2.3.1. Food Sources 
Vitamin B12 is found only in foods of animal origin [30]. Foods that are high in Vitamin B12  
include liver (26–58 μg (100 g)−1), beef and lamb (1–3 μg (100 g)−1), chicken (trace-1 μg (100 g)−1), 
eggs (1–2.5 μg (100 g)−1) and dairy foods (0.3–2.4 μg (100 g)−1). There are no naturally occurring 
bioactive forms of Vitamin B12 from plant sources. Some plant foods contain added Vitamin B12. Some 
foods that are contaminated or fermented by bacteria, e.g., tempeh and Thai fish sauce, have been 
reported to contain Vitamin B12 [31], although these may be poorly absorbed. In normal humans, the 
absorption of Vitamin B12 from foods has been shown to vary depending on the quantity and type of 
protein consumed [32]. 
2.3.2. Supplements 
Most people have no trouble getting the RDA of 2.4 mcg day−1 of Vitamin B12 from food.  
However, those who regularly consume a diet free of cheese, milk, dairy products and eggs may have a 
deficiency of this vitamin at any age [33]. The Vitamin B12 deficiency can be caused by malabsorption, 
a not vary or inadequate diet (especially in the elderly), by prolonged vegetarian or vegan diet or  
ovo-lacto diet. Furthermore, pregnant and/or lactating women following vegetarian or vegan diets are at high 
risk of deficiency due to the increased metabolic demand for Vitamin B12. Together with B Vitamin-fortified 
foods and supplements, these foods may constitute new alternatives to prevent Vitamin B12 deficiency in 
individuals consuming vegetarian diets. Furthermore, due to the increased probability of food-bound 
Vitamin B12 malabsorption with increasing age, it would be a good habit to set a nutritional program that 
includes the intake of Vitamin B12 through supplements or fortified foods (such as fortified cereals) [15]. 
Deficiency of Vitamin B12, though often undiagnosed, may affect a significant number of people, 
especially older adults. One symptom of Vitamin B12 deficiency is megaloblastic anemia, which is 
indistinguishable from that associated with folate deficiency. Large doses of folic acid given to an 
individual with an undiagnosed Vitamin B12 deficiency could correct megaloblastic anemia without 
correcting the underlying Vitamin B12 deficiency, leaving the individual at risk of developing irreversible 
neurologic damage [34]. 
The neurologic symptoms of Vitamin B12 deficiency include: numbness and tingling of the  
hands and, more commonly, the feet; difficulty walking; memory loss; disorientation; and dementia with or 
without mood changes. Although the progression of neurologic complications is generally gradual, such 
symptoms may not be reversed with treatment of Vitamin B12 deficiency, especially if they have been 
present for a long time. Neurologic complications are not always associated with megaloblastic anemia 
and are the only clinical symptom of Vitamin B12 deficiency in about 25% of cases [15]. Although 
Vitamin B12 deficiency is known to damage the myelin sheath covering cranial, spinal and  
peripheral nerves, the biochemical processes leading to neurological damage in Vitamin B12 deficiency 
are not yet fully understood [35]. 
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Because Vitamin B12 is a water soluble vitamin, it is difficult to overdose or build up  
Vitamin B12 toxicity. With water-soluble vitamins, the body excretes excess amounts in the urine, rather 
than storing them [36]. Because of the low toxicity of Vitamin B12, no tolerable upper intake level (UL) 
has been set by the U.S. Food and Nutrition Board [15]. While there are not very many side effects related 
to the high intake of Vitamin B12, excess supplementation may be associated with prostate cancer [37]. 
3. Bone, B Vitamins and Homocysteine 
Our skeleton is not an inert structure, but an active organ, made up of tissue and cells in a continual 
state of activity throughout a lifetime. The majority of bone mass is acquired during the growth phase of 
bone development [38,39]. The maximum amount of bone acquired is known as peak bone mass  
(PBM) [38,40]. Sixty to 80% of PBM is determined by genetics, while the remaining 20%–40% is 
influenced by lifestyle factors, primarily nutrition and physical activity [41]. It is important to achieve 
maximum PBM at a young age (before 30 years of age) in order to protect the skeleton against 
progressive bone loss associated with aging. From the moment the loss of bone tissue begins, the 
occurrence of osteoporosis with a high risk for fractures of the hip and spine becomes possible [42].  
The World Health Organization (WHO) defines osteopenia as the phase before osteoporosis; osteoporosis is 
a condition of increased bone fragility and susceptibility to fracture due to loss of bone mass. BMD, 
expressed as the amount of mineral present for given area/volume of bone, is a convenient clinical 
marker for evaluating bone mass and is associated with osteoporotic fracture risk [43]. In addition to 
BMD [39], there are other modifiable risk factors that play a role in the risk of osteoporotic fractures. Risk 
factors are generally cumulative [44] and include microarchitecture and bone geometry, balance, mobility, 
muscle strength and environmental factors. Bone microarchitecture, in addition to bone density, is also 
important for determining the status of bone health. A lower number of trabeculae and increased 
trabecular separation may represent one of the parameters to assess the risk of fractures. The evaluation 
of texture parameters, such as trabecular bone score (TBS) or average Hurst parameter (H), in addition 
to BMD and risk factors related to bone fragility, could help find, in groups of non-osteoporotic people, 
those who are at high risk of fractures [45]. Osteoporosis is a leading cause of morbidity and mortality in the 
elderly [46]. Regarding the prevalence of osteoporosis in Europe, it is estimated that by the year 2050, the 
number of men and women to be affected will be more than 30 million [47]. Osteoporosis influences 
quality of life, as well as life expectancy [48], because the major consequence of osteoporosis is 
fractures, and hip fractures are especially associated with institutionalization and increased mortality. In 
the year 2000, approximately nine million fractures occurred worldwide, leading to a loss of 5.8 million 
disability adjusted life-years (DALYs) [49]. Due to a rise in life expectancy, the economic burden of 
osteoporotic fractures in Europe is expected to increase substantially in the coming decades. 
Osteoporotic subjects represent a group of individuals at risk, and for this reason, there is growing 
interest among scientists and clinicians to search for specific nutrients capable of ensuring good bone 
health and preventing disease-related skeletal complications [50]. Until now, calcium and Vitamin D have 
been considered the primary objective of nutritional prevention of osteoporosis. Based on this review of 
the literature, it has emerged that other nutrients are also needed to maintain healthy bone. In particular, 
although more studies are needed, the proper intake of B Vitamin might improve bone health [51]. There are 
many hypotheses that explain the potential role of B Vitamins and/or homocysteine in bone health [1]. 
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In vitro studies have shown that slightly elevated concentrations of homocysteine (from 10 mmol L−1) 
increase osteoclast activity and bone resorption [52,53], leading in turn to an inhibitory effect of 
homocysteine on bone formation [54]. Kang and Trelstad found that homocysteine interfered with 
collagen cross-links from purified rat skin collagen [1]. Additional in vitro studies indicate that high 
concentrations of Hcy inhibit the activity of lysyl oxidase (an enzyme involved in cross-linking  
of collagen) and thereby stimulate osteoclast activity in elevated concentration [55–58]. Interference in 
cross-link formation would cause an altered bone matrix, resulting in more fragile bones [59]. 
Animal studies have shown that a deficiency in folic acid and Vitamins B6 and B12 can lead to 
increased levels of homocysteine and, consequently, an increased production of free radicals and  
oxidative stress, which lead to endothelial dysfunction [60,61], decreased bone blood flow and, eventually, 
osteoporosis [62]. Decreased bone blood flow would intuitively lead to bone disease from lack of 
nutrient delivery to the bone. However, these investigations do not demonstrate the causality between 
Hcy and changes in bone blood flow, and they do not provide any data regarding the mechanisms behind 
their observations [60]. Clemens et al. observed that mice deficient in the synthesis of Vitamin B12 have 
growth retardation and a comparative scarcity of osteoblasts. Evidence emerging in vivo suggests that 
Vitamin B12 may interfere with growth hormone signaling in these mice and exert its downstream 
effects on osteoblasts [63]. The Roman Garcia study has shown that Vitamin B12 deficiency in a genetic 
mouse model results in severe growth retardation post-weaning and osteoporosis, and the severity and 
time of onset of this phenotype in the offspring depends on the genotype of the mother. The study shows 
how Vitamin B12 plays a vital role by regulating positively post-weaning growth and bone formation 
through the synthesis of taurine, thus paving the way for potential therapies to increase bone mass [64]. 
Recently, increased plasma homocysteine (HCY) has been suggested to be an independent risk factor for 
osteoporotic fractures in elderly persons [2,65]. Little is known, however, about the mechanistic role of Hcy 
in osteoporosis. A link between Hcy and bone disease was first made in 1966, when McKusick [66,67] 
hypothesized a disturbed collagen cross-linking in patients with homocystinuria. 
Holstein et al. have demonstrated that high concentrations of homocysteine and S-adenosylhomocysteine 
in bone, as well as a low capacity of methylation, concern a morphology of reduced bone in humans [68]. 
Starting from in vitro [69] and in vivo data [70], they have concluded that there is an association between 
the altered bone morphology and high bone concentrations of homocysteine and S-adenosylhomocysteine, 
but not between bone morphology and impaired methylation ability [68]. The effect of subtle elevations 
of plasma hcy on bone health is difficult to demonstrate in human studies, as they are related to mixed 
results [13,15]. Some report an association between elevated plasma hcy and fracture risks [2,65,71], 
while others find no relationship [72–74]. However, it is not clear whether this is related to tHcy by itself, 
to the level of Vitamins B12, B6 or folate, which are required for its metabolism, or to other causes of 
elevated tHcy, such as environmental factors or underlying disease [75]. A recent meta-analysis of 
observational studies has found that elevated homocysteine levels and low vitamin B12 and folate levels 
have been associated with structural deterioration of bone tissue, and Vitamin B6 has been found to be 
deficient in people with hip fractures [3]. In another study, which examined older men and women, it 
has been shown that subjects who showed low plasma concentrations of Vitamin B6 (<20 nmol L−1) are 
associated with an altered morphology of human bone [76] and had a higher average annual bone loss 
than those with normal B6 concentrations [77]. It is also important to highlight that a study to investigate 
the effect of Vitamin B12 on osteoblast-related proteins showed that levels of osteocalcin and alkaline 
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phosphatase skeletal blood were lower in patients with Vitamin B12 deficiency. The results suggested 
that the activity of osteoblasts depends on Vitamin B12 and that bone metabolism is affected by  
Vitamin B12 deficiency, but still, it is not known whether the deficiency of Vitamin B12 produces  
clinically-significant bone disease [78]. The assessment of the association of Hcy and Vitamin B12 status 
and the combined effect of the two with broadband ultrasound attenuation (BUA), bone turnover markers 
and fracture on a group of subjects of the Longitudinal Aging Study Amsterdam led to the conclusion 
that high Hcy and low concentrations of Vitamin B12 were significantly associated with low BUA, high 
bone turnover markers and an increased risk of fracture [79]. 
Currently, there are few studies designed to evaluate the effect of folic acid and Vitamin B12 on 
lowering plasma homocysteine and the effects on bone health [80]. 
The Rotterdam study, regarding osteoporosis, BMD and the onset of vertebral fractures, showed  
that increased levels of homocysteine are a factor of strong and independent risk for osteoporotic 
fractures [2,81]. A related study, which has examined the association between intake of Hcy-related B 
Vitamin (riboflavin, pyridoxine, folate and Vitamin B12) and femoral neck bone mineral density  
(FN-BMD) and the risk of fracture in a large population-based cohort of elderly Caucasians concluded 
that increased dietary riboflavin and pyridoxine intake was associated with higher FN-BMD [82]. In a 
controlled clinical trial, Reynolds et al. studied the correlation between fracture risk and the lack of 
Vitamin B6, in particular of pyridoxal-5’-phosphate (PLP), the most important form of Vitamin B6 
present in human serum, concluding that PLP can be a causative factor for hip fracture under its role in 
the activity of a key regulatory protein [83]. 
In the Hordaland Homocysteine Study [84], folate has been linked to BMD and a reduced fracture 
risk [85], but there is limited evidence to support a direct mechanistic effect of folate on bone. 
In the Heart Outcomes Prevention Evaluation (HOPE) 2 of the trial, the effects of five years of  
vitamin supplementation (2.5 mg of folic acid, 50 mg of vitamin B 6 and 1 mg of Vitamin B 12 per day) on 
fractures were evaluated [86]. What emerged was that although the plasma levels of Hcy were  
reduced in the treatment group, there were no significant differences between treatment and placebo on 
the incidence of skeletal fractures [87]. The B-PROOF study (B Vitamins for the Prevention of 
Osteoporotic Fracture), a randomized controlled trial, tried to determine whether Vitamin B12 and folic 
acid supplementation reduces osteoporotic fracture incidence in hyperhomocysteinemic elderly 
individuals [88,89]. Data from this study show that combined Vitamin B12 and folic acid supplementation 
had no effect on osteoporotic fracture incidence in an elderly population. Since the treatment was also 
associated with a higher incidence of cancer, Vitamin B12 plus folic acid supplementation cannot be 
recommended at present for fracture prevention in elderly people [89]. The Vitatopos trial seems to 
confirm that treatment with B Vitamins had no effect on the incidence of osteoporotic fractures in treated 
patients [90]. The population studies can lead to inconsistencies in the results obtained due to both 
differences in study populations [59,91,92] and to heterogeneity between studies. The heterogeneity may 
be explained by the differences in the mean age of the study populations, differences in the mean status 
of Vitamin B12, folate and homocysteine, differences in the sex distribution of the study population and 
the duration of follow-up [3]. One randomized controlled trial, designed to determine in healthy elderly 
subjects whether lowering homocysteine with B Vitamins affects plasma biomarkers of bone turnover, 
led to the conclusion that supplementation with folic acid and Vitamins B-6 and B-12 lowered plasma 
homocysteine, but had no beneficial effect on bone turnover estimated from biomarkers of bone 
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formation and resorption [93]. In a two-year prospective, placebo-controlled, double-blind trial,  
Sato et al. [94] observed a strong reduction in fracture incidence in stroke patients who received high 
doses of folate and vitamin B12. In addition, low cobalamin status has been shown to reduce osteoblast 
activity [78]. 
Genetic Studies 
Several epidemiological studies have been performed investigating the relationship between MTHFR 
677C_T polymorphism in the gene that encodes for the MTHFR enzyme and bone health and fracture 
risk [3,9]. Methylene reductase physiologically catalyzes the conversion of 5,10-methylene-5-methylene, 
which is used for the methylation of homocysteine to methionine, thereby decreasing the concentration of 
homocysteine [8]. The 677C_T polymorphism in the MTHFR gene is widely reported as the most common 
genetic determinant of hyperhomocysteinemia (>15 μmol L−1) [95,96] and low erythrocyte folate 
concentrations [96,97]. Mendelian randomization studies show that homozygosity for the variant allele 
(TT genotype), which occurs at a rate of 10% in most ethnic groups, leads to 25% higher tHcy 
concentrations than occur in individuals with the common genotype (CC) [98]. The variant enzyme 
develops a greater propensity to dissociate from the FAD. Riboflavin (Vitamin B2) in the form of FAD 
acts as a cofactor for MTHFR. The supplementation with low-dose riboflavin could stabilize MTHFR 
activity in vivo in homozygous individuals [99]. The 677C_T polymorphism was associated with BMD 
at all measured sites, with a 23% increased risk for all fractures in individuals with the MTHFR 677TT 
genotype compared with those with the CT or CC genotypes [9,100]. The Aberdeen Osteoporosis 
Screening Study showed that a low intake of riboflavin (vitamin B2) in subjects with the TT genotype 
had a negative effect on the BMD of the femoral neck [101]. Studies have reported that individuals with 
the TT genotype and low folate levels (<9 nmol L−1) had a lower BMD than those with CC or CT genotypes 
at the same concentration of plasma folate, suggesting an important gene-nutrient interaction [102]. In 
support of these findings, a Danish Osteoporosis Prevention Study has concluded that individuals with 
the TT genotype had a significantly reduced BMD with low dietary intakes associated with various B 
Vitamins, including folic acid, B12, B6 and riboflavin [103]. Such findings provide evidence to support 
a detrimental effect of the polymorphism combined with low B Vitamin intakes on robust bone health 
outcomes (i.e., BMD and fracture risk) and indicate that B Vitamins may have the potential to modulate 
any negative effect of this polymorphism on bone health [1]. Many studies are designed to evaluate the 
association between the presence of MTHFR 667C_ T and the incidence of fractures and BMD, but often, 
the results were inconsistent. This trend could be explained by the different levels of plasma folate taken into 
account [8]. Factors such as differences in ethnicity (considerable variation in the frequency of this 
polymorphism between populations) and variation in the age of the populations investigated probably 
also contribute to inconsistencies among studies [1]. 
4. Conclusions 
There are still conflicting data regarding the relationship between high levels of homocysteine, low 
concentrations of B Vitamins and low bone mineral density. This epidemiological evidence is further 
reinforced by genetic studies that show an association between the common MTHFR 677C_T 
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polymorphism and the risk of osteoporosis. Certainly, mechanisms related to changes in collagen  
cross-linking may lead to a change in bone structure. 
Epidemiological cohort studies, however, show strong associations between low levels of  
Vitamin B12 and homocysteine serum concentrations and a high incidence of fractures. 
Additional studies are needed to show how low levels of Vitamin B are causally associated  
with the risk of osteoporosis and whether there are benefits given by the supplementation of Vitamin B 
for bone health. 
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